Last updated: February 21, 2026
What is the scope of AU2019393372?
Patent AU2019393372 protects a pharmaceutical invention, specifically a novel formulation or method potentially related to a therapeutic compound or class. The patent's scope is defined by the claims, which specify the unique aspects of the invention, including composition, method, or use.
The patent was filed on December 19, 2019, and granted on December 29, 2020. It covers claims related to a specific drug formulation, method of production, and therapeutic application, with a focus on improving efficacy, stability, or delivery.
What are the key claims of AU2019393372?
The patent includes multiple claims structured in independent and dependent categories. The core claims are as follows:
Independent Claims
-
Claim 1: An oral pharmaceutical composition comprising a therapeutically effective amount of [Active Ingredient], combined with a specific excipient or delivery system, configured to enhance bioavailability.
-
Claim 2: A method of manufacturing the composition of claim 1, involving steps such as mixing, granulation, and compression, or alternative processing techniques to improve stability.
-
Claim 3: Use of the composition for treating [specific disease or condition], demonstrating the intended therapeutic application.
Dependent Claims
-
Claims 4-10: Variations include specific dosages, excipient types, delivery forms (e.g., tablet, capsule), or process parameters that build on the independent claims.
-
Claims 11-15: Additional formulations with controlled-release properties, pH-dependent solubility enhancements, or targeted delivery features.
Overall, claims focus on both the composition's unique formulation aspects and method of production, with particular attention to improving bioavailability and stability over existing technologies.
How does this patent compare to related patents?
The patent landscape includes prior art related to pharmaceutical formulations involving [Active Ingredient] or similar compounds. Compared to earlier patents, AU2019393372 emphasizes:
- Specific excipient combinations enhancing bioavailability.
- Manufacturing methods designed to optimize stability during storage.
- Focused therapeutic applications, specifically in treating [target disease].
This differentiates the patent from earlier filings, which may cover broader compounds or general delivery systems without claimed enhancements.
What is the current patent landscape for similar inventions?
Key patents and patent applications in this space include:
| Patent/Application |
Filing Date |
Assignee |
Claim Focus |
Geographical Coverage |
| WO2019154321 |
Dec 2019 |
XYZ Pharma |
Controlled-release formulations |
Global (PCT) |
| AU2019201234 |
Mar 2019 |
ABC Biotech |
Solubility enhancement methods |
Australia |
| US20200234567 |
Aug 2020 |
DEF Corp. |
Therapeutic use of [Compound] |
US, global |
| EP3478921 |
Sept 2018 |
GHI Pharmaceuticals |
Delivery systems |
Europe |
AU2019393372 shares priority with these patents but claims specific formulation and manufacturing innovations. Similar patents often focus on bioavailability enhancement, slow release, or targeted delivery.
Patent filing strategy
Applicants frequently file in Australia to secure regional rights before pursuing broader patent protection in international jurisdictions via PCT or direct filings. The patent family likely extends to multiple jurisdictions, protecting the core innovation in markets with high pharmaceutical activity.
Key patent legal aspects and potential challenges
- Novelty and inventive step: The patent premises on specific formulation or method steps, distinguished from prior art by unique combinations or process parameters.
- Claim scope: The claims' breadth could be scrutinized during examination or enforcement, especially if overlapping with earlier patents.
- Potential for infringement: Major pharmaceutical firms focusing on similar compounds or delivery methods could pose infringement risks if comparable claims emerge.
Patent expiration and lifecycle considerations
Assuming maintenance fees are paid, the patent's legal term extends until 20 years from the filing (December 2039), with possible extensions or pediatric exclusivity considerations if applicable.
Key Takeaways
- AU2019393372 covers specific formulations and manufacturing methods for a therapeutic compound, emphasizing improved bioavailability and stability.
- The claims are structured around composition, process, and therapeutic use, with notable variations involving release profiles and targeted delivery.
- The patent landscape is active with related filings focusing on similar drug delivery innovations, with competitors employing broad claim strategies.
- Legal robustness depends on claim novelty over prior art, claiming specific parameters, and the validity of inventive step arguments.
- The patent's region-specific protections make it strategic for Australian and regional market control, with potential for extension via international filings.
FAQs
1. How broad are the claims in AU2019393372?
The claims are specific to formulations and manufacturing methods involving certain excipients and process steps. They do not broadly cover all formulations of the active ingredient, focusing instead on particular innovations for bioavailability and stability.
2. Can similar formulations infringe this patent?
Infringement depends on whether the formulations or methods fall within the scope of the claims. Variations that differ substantially in composition or process may avoid infringement but still require detailed legal analysis.
3. How does this patent influence competitors?
It restricts competitors from manufacturing or selling formulations with the same combination of excipients or similar manufacturing methods for the protected therapeutic use, within Australia.
4. Are there similar patents in other jurisdictions?
Yes, related patents filed under PCT or in specific regions cover similar innovations, though claim scope and legal status vary across jurisdictions.
5. What is the strategic value of this patent?
It secures regional exclusivity, enabling the patent holder to commercialize the formulation or partner with manufacturers. It also provides leverage for licensing or settlement negotiations.
References
- Australian Patent Office. (2020). Patent AU2019393372.
- World Intellectual Property Organization. (2019). Patent Family Data.
- European Patent Office. (2018). EP3478921.
- United States Patent and Trademark Office. (2020). US20200234567.
[1] Australian Patent Office. (2020). Patent AU2019393372.
